Business ❯ Pharmaceuticals

Mergers and Acquisitions

Corporate Strategy Pfizer Investment Legal Disputes Biontech Antitrust Issues Takeover Bids Bidding Wars Sanofi Market Strategy Drug Development Acquisition Strategies Federal Trade Commission Biotechnology Investment Funds Foreign Investment Rare Diseases Company Acquisitions Tender Offer AstraZeneca Bristol Myers Squibb Pharma Industry Corporate Transactions BioNTech Healthcare Acquisition Transactions Valuation Weight-loss Drugs Novartis Weight Loss Competitive Strategy Company Strategy Obesity Treatments Corporate News Corporate Competition Novo Nordisk vs Pfizer Antitrust Law Market Competition Novo Nordisk BioMarin Company Acquisition Acquisitions Market Trends

BioMarin to Buy Alesta for $275 Million to Add Oral HPP Drug

Funded from cash on hand, the purchase brings ALE1 into BioMarin’s rare-skeletal portfolio, signaling a push to scale clinical-stage therapies.

Angelini Pharma to Acquire Catalyst Pharmaceuticals for $4.1 Billion in Cash

Novartis to Acquire Excellergy in Up to $2 Billion Deal for Next-Gen Anti-IgE

Merck to Acquire Terns for $6.7 Billion to Add Promising Leukemia Drug

Merck Reportedly Weighs $28–$32 Billion Deal for Revolution Medicines After AbbVie Denial

Amgen Buys Oxford Spinout Dark Blue Therapeutics for Up to $840 Million

BioMarin to Acquire Amicus for $4.8 Billion in Cash

Lundbeck Challenges Alkermes With Up to $23-Per-Share Offer for Avadel

Pfizer Clinches $10 Billion Metsera Deal After Novo Nordisk Withdraws

Pfizer Wins Metsera With $10 Billion Cash‑Plus‑CVR Offer as Novo Withdraws

Metsera Backs Pfizer’s $10 Billion Deal, Citing Regulatory Risks in Novo Bid

Novo Nordisk Raises Metsera Bid to $10 Billion, Outpacing Pfizer’s $8.1 Billion Counter

Pfizer Sues Metsera and Novo Nordisk to Block Termination of $4.9 Billion Deal

Pfizer Wins Early U.S. Antitrust Clearance for Metsera Deal as Novo’s Higher Bid Pressures Timeline

Pfizer Strikes U.S. Drug-Pricing Pact, Wins Exemption From 100% Import Tariff

Pfizer to Buy Metsera in Up to $7.3 Billion Obesity Bet

Novartis to Acquire Tourmaline Bio for $1.4 Billion to Bolster Heart-Drug Pipeline

Merck to Acquire Verona Pharma in $10 Billion Deal for Ohtuvayre COPD Therapy